Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

Ongoing Story· Today

Obesity Drug Wegovy Shows Promise in Young Children in New Study

3 developments

KipaHealth

Weight Loss Drug Semaglutide Shows Promise in Children Aged 6

Translated & summarized from Kipa by baba

Religious-rightNeutral tone

Hebrew · 4 newsrooms covering

A clinical trial found that the weight loss drug Wegovy (semaglutide) significantly reduced BMI in children aged 6 to under 12 with obesity, with nearly 80% achieving a 10% BMI reduction compared to none in the placebo group. The study, which included dietary and exercise support, showed an average BMI decrease of 17.4% over 68 weeks for those on Wegovy. While safety appears comparable to adult studies, long-term effects and sustained weight loss remain under investigation, and regulatory approval for younger children is pending.

The story in 5 lines · by baba

  • Wegovy (semaglutide) achieved an average 17.4% BMI reduction in obese children aged 6-12 over 68 weeks.
  • Nearly 80% of children on Wegovy saw at least a 10% BMI reduction, versus 0% on placebo.
  • The drug's safety profile in children was similar to that seen in adult studies.
  • Long-term effects and sustained weight loss after treatment cessation require further study.
  • Regulatory approval for Wegovy use in children under 12 is pending.
Weight Loss Drug Semaglutide Shows Promise in Children Aged 6
Editorial illustration generated by baba News, not a photograph of the event.

A recent advanced clinical trial has demonstrated significant results for Wegovy (semaglutide), a weight loss injection already approved for adults and adolescents, when administered to children aged 6 to under 12 who are suffering from obesity. According to data released by the drug's manufacturer, Novo Nordisk, nearly 80% of the children who received the medication achieved at least a 10% reduction in their Body Mass Index (BMI), a stark contrast to the 0% observed in the placebo group. It is important to note that this figure refers to BMI reduction, not necessarily a 10% decrease in overall body weight. The findings from the STEP Young trial are set to be presented at the Obesity Week conference and published in The New England Journal of Medicine. Over 85% of the participating children had severe obesity at the trial's commencement.

The Phase 3 trial involved weekly injections of semaglutide or a placebo. Both groups received a comprehensive support program including a reduced-calorie diet and increased physical activity, ensuring the study measured the drug's added benefit. After 68 weeks, the Wegovy group experienced an average BMI reduction of 17.4%, while the placebo group saw a slight increase of 2.2%. Any degree of BMI reduction was observed in 83% of children on Wegovy, compared to 23.5% in the placebo group. Furthermore, one analysis indicated that 38.4% of children in the Wegovy group dropped below the obesity threshold, versus 2.1% in the placebo group. However, falling below the obesity threshold does not guarantee a return to a healthy weight range or sustained results after treatment cessation.

Novo Nordisk reported that the drug's safety profile in this trial was consistent with previous studies on semaglutide, with no unexpected findings regarding growth or sexual development. Nevertheless, the current trial duration does not fully address the effects of long-term treatment in children or the durability of weight loss after discontinuing the medication. In Israel, Wegovy's current approved indication for obesity in adolescents begins at age 12 under specific conditions. The results for younger children do not automatically grant approval for this age group, and further regulatory authorization is pending for its use in younger populations.

KipaRight · Jerusalem

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

Mentioned

Full coverage · 5 outlets
First: Kan News · Nov 16

The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.

Related stories · 2

Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.

Open the Wire